Asthma and chronic obstructive pulmonary disease are prevalent conditions associated with sudden, symptomatic decline in respiratory function requiring urgent treatment. Management of acute airflow obstruction includes frequent, thorough assessments as well as timely administration of supplemental oxygen, corticosteroids and inhalational drug delivery of short acting bronchodilators. The benefits of inhaled administration of aerosolized short-acting bronchodilators include rapid symptom relief and improvements in lung function with fewer side effects. To optimize these benefits requires an understanding of the factors concerning aerosol delivery in the acute care setting that include patient age, severity of airway obstruction, aerosol generating device and the patient and device interface. Treatment strategies have been developed that include increased dosing of short-acting bronchodilators, combined administration of β-agonist and anticholinergic bronchodilators, continuous drug delivery and the use of helium to enhance lower respiratory tract drug deposition and improve patient outcomes.
BuistAS, McBurnieMA, VollmerWM, GillespieS, BurneyP, ManninoDM, et al.International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet., 2007; 370(9589):741–750. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17765523
2.
BaleG, Marti'nez-CamblorP, BurgePS, SorianoJB. Long-term mortality follow-up of the ISOLDE participants: causes of death during 13 years after trial completion. Respir Med., 2008; 102(10):1468–1472. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18620853
Chronic obstructive pulmonary disease among adults–United States, 2011. MMWR Morb Mortal Wkly Rep. 2012; 61(46):938–943. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23169314
5.
DivoM, CoteC, de TorresJP, CasanovaC, MarinJM, Pinto-PlataV, et al.Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med., 2012; 186(2):155–161. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22561964
TsaiC-L, SobrinoJA, CamargoCA. National study of emergency department visits for acute exacerbation of chronic obstructive pulmonary disease, 1993–2005. Acad Emerg Med., 2008; 15(12):1275–1283. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18976335
10.
WuS, BakerC, LangME, SchragerSM, LileyFF, PapaC, et al.Nebulized hypertonic saline for bronchiolitis: a randomized clinical trial. JAMA Pediatr., 2014; 168(7):657–663. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24862623
11.
PlintAC, JohnsonDW, PatelH, WiebeN, CorrellR, BrantR, et al.Epinephrine and dexamethasone in children with bronchiolitis. N Engl J Med., 2009; 360(20):2079–2089. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19439742
12.
DaviskasE, RobinsonM, AndersonSD, ByePTP. Osmotic stimuli increase clearance of mucus in patients with mucociliary dysfunction. J Aerosol Med., 2002; 15(3):331–341. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12396422
13.
DaviskasE, RubinBK. Effect of inhaled dry powder mannitol on mucus and its clearance. Expert Rev Respir Med., 2013; 7(1):65–75. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23362816
14.
WarkPA, McDonaldV. Nebulised hypertonic saline for cystic fibrosis. Cochrane database Syst Rev. 2003;(1):CD001506. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12535409
15.
GesslerT, SeegerW, SchmehlT. Inhaled prostanoids in the therapy of pulmonary hypertension. J Aerosol Med Pulm Drug Deliv., 2008; 21(1):1–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18518827
16.
De LucaD, ZeccaE, PiastraM, RomagnoliC. Iloprost as “rescue” therapy for pulmonary hypertension of the neonate. Paediatr Anaesth., 2007; 17(4):394–395. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17359413
FinkJ, DhandR. Bronchodilator resuscitation in the emergency department. Part 2 of 2: dosing strategies. Respir Care., 2000; 45(5):497–512. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10813227
19.
RodrigoG, RodrigoC. Metered dose inhaler salbutamol treatment of asthma in the ED: Comparison of two doses with plasma levels. Am J Emerg Med., 1996; 14(2):144–150. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8924135
20.
McFaddenER, StraussL, HejalR, GalanG, DixonL. Comparison of two dosage regimens of albuterol in acute asthma. Am J Med., 1998; 105(1):12–17. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9688015
21.
EmermanCL, CydulkaRK, McFaddenER. Comparison of 2.5 vs 7.5 mg of inhaled albuterol in the treatment of acute asthma. Chest., 1999; 115(1):92–96. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9925067
22.
RobertsonCF, SmithF, BeckR, LevisonH. Response to frequent low doses of nebulized salbutamol in acute asthma. J Pediatr., 1985; 106(4):672–674. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3981324
23.
DouglasJG, RaffertyP, FergussonRJ, PrescottRJ, CromptonGK, GrantIW. Nebulised salbutamol without oxygen in severe acute asthma: how effective and how safe? Thorax., 1985; 40(3):180–183. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC460020
24.
SchuhS, ReiderMJ, CannyG, PenderE, ForbesT, TanYK, et al.Nebulized albuterol in acute childhood asthma: comparison of two doses. Pediatrics., 1990; 86(4):509–513. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2216613
25.
StraussL, HejalR, GalanG, DixonL, McFaddenER. Observations on the effects of aerosolized albuterol in acute asthma. Am J Respir Crit Care Med., 1997; 155(2):454–458. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9032178
26.
NowakR, EmermanC, HanrahanJP, ParseyM V., HananiaNA, ClausR, et al.A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med., 2006; 24(3):259–267. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16635694
27.
HardasmalaniMD, DeBariV, BithoneyWG, GoldN. Levalbuterol versus racemic albuterol in the treatment of acute exacerbation of asthma in children. Pediatr Emerg Care. 2005; 21(7):415–419. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16027572
28.
QureshiF, ZaritskyA, WelchC, MeadowsT, BurkeBL. Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. Ann Emerg Med., 2005; 46(1):29–36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15988423
29.
AndrewsT, McGinteeE, MittalMK, TylerL, ChewA, ZhangX, et al.High-dose continuous nebulized levalbuterol for pediatric status asthmaticus: a randomized trial. J Pediatr., 2009; 155(2):205–210.e1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19464028
30.
CalvoGM, CalvoAM, MarfnHF, MoyaGJ. Is it useful to add an anticholinergic treatment to beta 2-adrenergic medication in acute asthma attack? J Investig Allergol Clin Immunol. 1998; 8(1):30–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9555617
31.
CookJJ, FergussonDM, DawsonKP. Ipratropium and fenoterol in the treatment of acute asthma. Pharmatherapeutica., 1985; 4(6):383–386. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2934747
32.
GuillMF, MaloneyMJ, DuRantRH. Comparison of inhaled metaproterenol, inhaled atropine sulfate, and their combination in treatment of children with acute asthma. Ann Allergy., 1987; 59(5):367–371. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3318574
33.
TeohL, CatesCJ, HurwitzM, AcworthJP, van AsperenP, ChangAB. Anticholinergic therapy for acute asthma in children. Cochrane database Syst Rev., 2012; 4:CD003797. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22513916
34.
RodrigoGJ, RodrigoC. First-line therapy for adult patients with acute asthma receiving a multiple-dose protocol of ipratropium bromide plus albuterol in the emergency department. Am J Respir Crit Care Med., 2000; 161(6):1862–1868. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10852758
35.
RodrigoGJ, Castro-RodriguezJA. Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis. Thorax., 2005; 60(9):740–746. Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1747524
36.
GriffithsB, DucharmeFM. Combined inhaled anticholinergics and short-acting beta2-agonists for initial treatment of acute asthma in children. Cochrane database Syst Rev., 2013; 8:CD000060. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23966133
37.
BackmanR, HellstromP-E. Fenoterol and ipratropium bromide in respirator treatment of patients with chronic bronchitis. Curr Ther Res - Clin Exp. 1985; 38(1):135–140.
38.
RebuckAS, ChapmanKR, AbboudR, ParePD, KreismanH, WolkoveN, et al.Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med., 1987; 82(1):59–64. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2879458
39.
LloberesP, RamisL, MontserratJM, SerraJ, CampistolJ, PicadoC, et al.Effect of three different bronchodilators during an exacerbation of chronic obstructive pulmonary disease. Eur Respir J., 1988; 1(6):536–539. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2971565
McCroryDC, BrownCD. Anti-cholinergic bronchodilators versus beta2-sympathomimetic agents for acute exacerbations of chronic obstructive pulmonary disease. Cochrane database Syst Rev. 2002;(4):CD003900. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12519615
42.
In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. COMBIVENT Inhalation Aerosol Study Group. Chest. 1994; 105(5):1411–1419. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8181328
43.
GrossN, TashkinD, MillerR, OrenJ, ColemanW, LinbergS. Inhalation by nebulization of albuterol-ipratropium combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary disease. Dey Combination Solution Study Group. Respiration., 1998; 65(5):354–362. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9782217
PatrickDM, DalesRE, StarkRM, LaliberteG, DickinsonG. Severe exacerbations of COPD and asthma. Incremental benefit of adding ipratropium to usual therapy. Chest., 1990; 98(2):295–297. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2142915
46.
EdmondsML, MilanSJ, BrennerBE, CamargoCA, RoweBH. Inhaled steroids for acute asthma following emergency department discharge. Cochrane database Syst Rev., 2012; 12:CD002316. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23235590
47.
NakanishiAK, KlasnerAK, RubinBK. A randomized controlled trial of inhaled flunisolide in the management of acute asthma in children. Chest., 2003; 124(3):790–794. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12969999
48.
MiriciA, MetalM, AkgunM. Comparison of the efficacy of nebulised budesonide with parenteral corticosteroids in the treatment of acute exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig., 2003; 23(1):55–62. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23319094
49.
MoriceAH, MorrisD, Lawson-MatthewP. A comparison of nebulized budesonide with oral prednisolone in the treatment of exacerbations of obstructive pulmonary disease. Clin Pharmacol Ther., 1996; 60(6):675–678. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8988070
50.
MaltaisF, OstinelliJ, BourbeauJ, TonnelAB, JacquemetN, HaddonJ, et al.Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med., 2002; 165(5):698–703. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11874817
51.
RodrigoG, RodrigoC. Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med., 1998; 157(3 Pt 1):698–703. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9517578
52.
GunenH, HacievliyagilSS, YetkinO, GulbasG, MutluLC, InE. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J., 2007; 29(4):660–667. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17251232
53.
McKenzieJE, Cruz-RiveraM. Compatibility of budesonide inhalation suspension with four nebulizing solutions. Ann Pharmacother., 2004; 38(6):967–972. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15084687
54.
DolovichMB, DhandR. Aerosol drug delivery: developments in device design and clinical use. Lancet., 2011; 377(9770):1032–1045. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21036392
55.
LaubeBL, JanssensHM, de JonghFHC, DevadasonSG, DhandR, DiotP, et al.What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J., 2011; 37(6):1308–1331. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21310878
56.
CatesCJ, WelshEJ, RoweBH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane database Syst Rev., 2013; 9:CD000052. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24037768
57.
RubinBK, FinkJB. The delivery of inhaled medication to the young child. Pediatr Clin North Am., 2003; 50(3):717–731. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12877243
58.
AmiravI, NewhouseMT. Review of optimal characteristics of face-masks for valved-holding chambers (VHCs). Pediatr Pulmonol., 2008; 43(3):268–274. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18219694
59.
HessD, FisherD, WilliamsP, PoolerS, KacmarekRM. Medication nebulizer performance. Effects of diluent volume, nebulizer flow, and nebulizer brand. Chest., 1996; 110(2):498–505. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8697857
60.
ItogaNK, KinoshitaCK, MasutaniSM, YamamotoLG. Mechanical factors affecting nebulized albuterol aerosol particle sizes for asthma drug delivery. Am J Emerg Med., 2014; 32(6):569–572. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24666740
61.
SabatoK, WardP, HawkW, GildengorinV, AsselinJM. Randomized controlled trial of a breath- actuated nebulizer in pediatric asthma patients in the emergency department. Respir Care. 2011; 56(6):761–770. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21333060
62.
ArunthariV, BruinsmaRS, LeeAS, JohnsonMM. A prospective, comparative trial of standard and breath-actuated nebulizer: efficacy, safety, and satisfaction. Respir Care., 2012; 57(8):1242–1247. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22348319
63.
WaldrepJC, DhandR. Advanced nebulizer designs employing vibrating mesh/aperture plate technologies for aerosol generation. Curr Drug Deliv., 2008; 5(2):114–119. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18393813
64.
NakanishiAK, LambBM, FosterC, RubinBK. Ultrasonic nebulization of albuterol is no more effective than jet nebulization for the treatment of acute asthma in children. Chest., 1997; 111(6):1505–1508. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9187164
65.
DolovichMB, AhrensRC, HessDR, AndersonP, DhandR, RauJL, et al.Device selection and outcomes of aerosol therapy: Evidence-based guidelines: American College of Chest Physicians/American College of Asthma, Allergy, and Immunology. Chest., 2005; 127(1):335–371. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15654001
66.
TurnerJR, CorkeryKJ, EckmanD, GelbAM, LipavskyA, SheppardD. Equivalence of continuous flow nebulizer and metered-dose inhaler with reservoir bag for treatment of acute airflow obstruction. Chest., 1988; 93(3):476–481. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3342656
67.
SummerW, ElstonR, TharpeL, NelsonS, HaponikEF. Aerosol bronchodilator delivery methods. Relative impact on pulmonary function and cost of respiratory care. Arch Intern Med., 1989; 149(3):618–623. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2919938
68.
SalzmanGA, SteeleMT, PribbleJP, ElenbaasRM, PyszczynskiDR. Aerosolized metaproterenol in the treatment of asthmatics with severe airflow obstruction. Comparison of two delivery methods. Chest., 1989; 95(5):1017–1020. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2707058
69.
IdrisAH, McDermottMF, RaucciJC, MorrabelA, McGorrayS, HendelesL. Emergency department treatment of severe asthma. Metered-dose inhaler plus holding chamber is equivalent in effectiveness to nebulizer. Chest., 1993; 103(3):665–672. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8449049
70.
ColaconeA, AfilaloM, WolkoveN, KreismanH. A comparison of albuterol administered by metered dose inhaler (and holding chamber) or wet nebulizer in acute asthma. Chest., 1993; 104(3):835–841. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8365298
LevittMA, GambrioliEF, FinkJB. Comparative trial of continuous nebulization versus metered-dose inhaler in the treatment of acute bronchospasm. Ann Emerg Med., 1995; 26(3):273–277. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7661413
73.
RaimondiAC, SchottlenderJ, LombardiD, MolfinoNA. Treatment of acute severe asthma with inhaled albuterol delivered via jet nebulizer, metered dose inhaler with spacer, or dry powder. Chest., 1997; 112(1):24–28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9228352
74.
MandelbergA, ChenE, NoviskiN, PrielIE. Nebulized wet aerosol treatment in emergency department–is it essential? Comparison with large spacer device for metered-dose inhaler. Chest., 1997; 112(6):1501–1505. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9404745
75.
DhuperS, ChandraA, AhmedA, BistaS, MoghekarA, VermaR, et al.Clinical efficacy of racemic albuterol versus levalbuterol for the treatment of acute pediatric asthma. J Emerg Med., 2011; 40(3):247–255. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19081697
ChouKJ, CunninghamSJ, CrainEF. Metered-dose inhalers with spacers vs nebulizers for pediatric asthma. Arch Pediatr Adolesc Med., 1995; 149(2):201–205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7849885
78.
WilliamsJR, BothnerJP, SwantonRD. Delivery of albuterol in a pediatric emergency department. Pediatr Emerg Care., 1996; 12(4):263–267. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8858649
79.
BatraV, SethiGR, SachdevHP. Comparative efficacy of jet nebulizer and metered dose inhaler with spacer device in the treatment of acute asthma. Indian Pediatr. 1997; 34(6):497–503. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9357205
80.
RobertsonCF, NordenMA, FitzgeraldDA, ConnorFL, Van AsperenPP, CooperPJ, et al.Treatment of acute asthma: salbutamol via jet nebuliser vs spacer and metered dose inhaler. J Paediatr Child Health., 1998; 34(2):142–146. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9588637
81.
SchuhS, JohnsonDW, StephensD, CallahanS, WindersP, CannyGJ. Comparison of albuterol delivered by a metered dose inhaler with spacer versus a nebulizer in children with mild acute asthma. J Pediatr., 1999; 135(1):22–27. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10393599
82.
RubilarL, Castro-RodriguezJA, GirardiG. Randomized trial of salbutamol via metered-dose inhaler with spacer versus nebulizer for acute wheezing in children less than 2 years of age. Pediatr Pulmonol., 2000; 29(4):264–269. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10738013
83.
PloinD, ChapuisFR, StammD, RobertJ, DavidL, ChatelainPG, et al.High-dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: A double-blind, randomized equivalence trial. Pediatrics., 2000; 106(2 Pt 1):311–317. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10920157
84.
LevershaAM, CampanellaSG, AickinRP, AsherMI. Costs and effectiveness of spacer versus nebulizer in young children with moderate and severe acute asthma. J Pediatr., 2000; 136(4):497–502. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10753248
85.
DuarteM, CamargosP. Efficacy and safety of a home-made non-valved spacer for bronchodilator therapy in acute asthma. Acta Paediatr., 2002; 91(9):909–913. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12412864
86.
NewmanKB, MilneS, HamiltonC, HallK. A comparison of albuterol administered by metered-dose inhaler and spacer with albuterol by nebulizer in adults presenting to an urban emergency department with acute asthma. Chest., 2002; 121(4):1036–1041. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11948030
87.
EverardML. Inhaler devices in infants and children: challenges and solutions. J Aerosol Med., 2004; 17(2):186–195. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15294070
88.
ErzingerS, SchueeppKG, Brooks-WildhaberJ, DevadasonSG, WildhaberJH. Facemasks and aerosol delivery in vivo. J Aerosol Med., 2007; 20(Suppl 1):S78–S83; discussion S83-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17411409
89.
SangwanS, GursesBK, SmaldoneGC. Facemasks and facial deposition of aerosols. Pediatr Pulmonol., 2004; 37(5):447–452. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15095329
90.
LinH-L, RestrepoRD, GardenhireDS, RauJL. Effect of face mask design on inhaled mass of nebulized albuterol, using a pediatric breathing model. Respir Care., 2007; 52(8):1021–1026. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17650358
HessDR. Aerosol delivery devices in the treatment of asthma. Respir Care. 2008; 53(6):699–723; discussion 723-5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18501026
MahlerDA, WatermanLA, GiffordAH. Prevalence and COPD phenotype for a suboptimal peak inspiratory flow rate against the simulated resistance of the Diskus® dry powder inhaler. J Aerosol Med Pulm Drug Deliv., 2013; 26(3):174–179. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23025451
95.
T0nnesenF, LaursenLC, EvaldT, StahlE, IbsenTB. Bronchodilating effect of terbutaline powder in acute severe bronchial obstruction. Chest., 1994; 105(3):697–700. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8131527
96.
NanaA, YoungchaiyudP, MaranetraN, BoeJ, LofdahlCG, SelroosO, et al.Beta 2-agonists administered by a dry powder inhaler can be used in acute asthma. Respir Med., 1998; 92(2):167–172. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9616507
97.
DrblikS, LapierreG, ThiviergeR, TurgeonJ, GaudreaultP, Cummins-McManusB, et al.Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode. Arch Dis Child., 2003; 88(4):319–323. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1719510&tool=pmcentrez&rendertype=abstract
98.
LodhaR, GuptaG, BaruahBP, NagpalR, KabraSK. Metered dose inhaler with spacer versus dry powder inhaler for delivery of salbutamol in acute exacerbations of asthma: a randomized controlled trial. Indian Pediatr. 2004; 41(1):15–20. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14767083
99.
RodrigoGJ, RodrigoC. Continuous vs intermittent beta-agonists in the treatment of acute adult asthma: a systematic review with meta-analysis. Chest., 2002; 122(1):160–165. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12114352
100.
ColaconeA, WolkoveN, SternE, AfilaloM, RosenthalTM, KreismanH. Continuous nebulization of albuterol (salbutamol) in acute asthma. Chest., 1990; 97(3):693–697. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2306971
101.
LinRY, SauterD, NewmanT, SirleafJ, WaltersJ, TavakolM. Continuous versus intermittent albuterol nebulization in the treatment of acute asthma. Ann Emerg Med., 1993; 22(12):1847–18453. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8239106
102.
RudnitskyGS, EberleinRS, SchoffstallJM, MazurJE, SpiveyWH. Comparison of intermittent and continuously nebulized albuterol for treatment of asthma in an urban emergency department. Ann Emerg Med., 1993; 22(12):1842–1846. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8239105
103.
ReisnerC, KotchA, DworkinG. Continuous versus frequent intermittent nebulization of albuterol in acute asthma: a randomized, prospective study. Ann Allergy Asthma Immunol., 1995; 75(1):41–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7621059
104.
ShresthaM, BidadiK, GourlayS, HayesJ. Continuous vs intermittent albuterol, at high and low doses, in the treatment of severe acute asthma in adults. Chest., 1996; 110(1):42–47. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8681661
105.
Besbes-OuanesL, NouiraS, ElatrousS, KnaniJ, BoussarsarM, AbrougF. Continuous versus intermittent nebulization of salbutamol in acute severe asthma: a randomized, controlled trial. Ann Emerg Med., 2000; 36(3):236–268. Available from: http://www.urgencemonastir.com/pdf/urgencemonastirpublication20.pdf
CamargoCA, SpoonerCH, RoweBH. Continuous versus intermittent beta-agonists in the treatment of acute asthma. Cochrane database Syst Rev. 2003;(4):CD001115. Available from: http://www.ncbi.nlm.nih.gov/pubmed/14583926
108.
KhineH, FuchsSM, SavilleAL. Continuous vs intermittent nebulized albuterol for emergency management of asthma. Acad Emerg Med., 1996; 3(11):1019–1024. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8922008
109.
PapoMC, FrankJ, ThompsonAE. A prospective, randomized study of continuous versus intermittent nebulized albuterol for severe status asthmaticus in children. Crit Care Med., 1993; 21(10):1479–1486. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8403956
110.
MolerFW, JohnsonCE, Van LaanenC, PalmisanoJM, NasrSZ, AkingbolaO. Continuous versus intermittent nebulized terbutaline: plasma levels and effects. Am J Respir Crit Care Med., 1995; 151(3 Pt 1):602–626. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7881645
BerlinskiA, WillisJR, LeisenringT. In-vitro comparison of 4 large-volume nebulizers in 8 hours of continuous nebulization. Respir Care., 2010; 55(12):1671–1679. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21122175
113.
HessDR, FinkJB, VenkataramanST, KimIK, MyersTR, TanoBD. The history and physics of heliox. Respir Care., 2006; 51(6):608–612. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16723037
TassauxD, JollietP, RoeselerJ, ChevroletJC. Effects of helium-oxygen on intrinsic positive end-expiratory pressure in intubated and mechanically ventilated patients with severe chronic obstructive pulmonary disease. Crit Care Med., 2000; 28(8):2721–2728. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10966241
116.
LeeDL, LeeH, ChangH-W, ChangAYW, LinS-L, HuangY-CT. Heliox improves hemodynamics in mechanically ventilated patients with chronic obstructive pulmonary disease with systolic pressure variations. Crit Care Med., 2005; 33(5):968–973. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15891322
PivaJP, Menna BarretoSS, ZelmanovitzF, AmanteaS, CoxP. Heliox versus oxygen for nebulized aerosol therapy in children with lower airway obstruction. Pediatr Crit Care Med., 2002; 3(1):6–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12793914
119.
KressJP, NothI, GehlbachBK, BarmanN, PohlmanAS, MillerA, et al.The utility of albuterol nebulized with heliox during acute asthma exacerbations. Am J Respir Crit Care Med., 2002; 165(9):1317–1321. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11991886
120.
O’CallaghanC, WhiteJ, JacksonJ, CrosbyD, DougillB, BlandH. The effects of Heliox on the output and particle-size distribution of salbutamol using jet and vibrating mesh nebulizers. J Aerosol Med., 2007; 20(4):434–444. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18158716
121.
GoodeML, FinkJB, DhandR, TobinMJ. Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation. Am J Respir Crit Care Med., 2001; 163(1):109–114. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11208634
122.
CorcoranTE, DauberJH, ChigierN, IaconoAT. Improving drug delivery from medical nebulizers: the effects of increased nebulizer flow rates and reservoirs. J Aerosol Med., 2002; 15(3):271–282. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12396415
123.
DebinskiW, KtossowskiM, GembickaD. Effect of breathing of a helium-oxygen mixture on the adaptation of the organism to exercise. Acta Physiol Pol. 2015; 35(3):285–292. Available from: http://www.ncbi.nlm.nih.gov/pubmed/6537722
124.
JollietP, TassauxD, ThouretJM, ChevroletJC. Beneficial effects of helium:oxygen versus air:oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease. Crit Care Med., 1999; 27(11):2422–2429. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10579259
125.
JaberS, FodilR, CarlucciA, BoussarsarM, PigeotJ, LemaireF, et al.Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med., 2000; 161(4 Pt 1):1191–1200. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10764311
126.
KudukisTM, ManthousCA, SchmidtGA, HallJB, WylamME. Inhaled helium-oxygen revisited: effect of inhaled helium-oxygen during the treatment of status asthmaticus in children. J Pediatr., 1997; 130(2):217–224. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9042123
MoraaI, SturmanN, McGuireT, van DrielML. Heliox for croup in children. Cochrane database Syst Rev., 2013; 12:CD006822. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24318607
129.
ColebournCL, BarberV, YoungJD. Use of helium-oxygen mixture in adult patients presenting with exacerbations of asthma and chronic obstructive pulmonary disease: a systematic review. Anaesthesia., 2007; 62(1):34–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17156225
130.
ChowdhuryMM, McKenzieSA, PearsonCC, CarrS, PaoC, ShahAR, et al.Heliox therapy in bronchiolitis: phase III multicenter double-blind randomized controlled trial. Pediatrics., 2013; 131(4):661–669. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23509160
131.
RodrigoG, PollackC, RodrigoC, RoweBH. Heliox for nonintubated acute asthma patients. Cochrane database Syst Rev. 2006;(4):CD002884. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17054154
132.
DhandR. Aerosol therapy in patients receiving noninvasive positive pressure ventilation. J Aerosol Med Pulm Drug Deliv., 2012; 25(2):63–78. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22191396
133.
EsquinasA. Gas heliox during non-invasive mechanical ventilation in COPD. A randomised controlled pilot study. Am J Respir Crit Care Med., 2001; 161:A557.
134.
JollietP, TassauxD, RoeselerJ, BurdetL, BroccardA, D’HooreW, et al.Helium-oxygen versus ai r-oxygen noninvasive pressure support in decompensated chronic obstructive disease: A prospective, multicenter study. Crit Care Med., 2003; 31(3):878–884. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12627000
135.
MaggioreSM, RichardJ-CM, AbrougF, DiehlJL, AntonelliM, SauderP, et al.A multicenter, randomized trial of noninvasive ventilation with helium-oxygen mixture in exacerbations of chronic obstructive lung disease. Crit Care Med., 2010; 38(1):145–151. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19730250
136.
RodrigoG, PollackC, RodrigoC, RoweB. Heliox for treatment of exacerbations of chronic obstructive pulmonary disease. Cochrane database Syst Rev. 2002;(2):CD003571. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12076487
137.
AndersonM, SvartengrenM, BylinG, PhilipsonK, CamnerP. Deposition in asthmatics of particles inhaled in air or in helium-oxygen. Am Rev Respir Dis., 1993; 147(3):524–528. Available from: http://www.ncbi.nlm.nih.gov/pubmed/8442582
138.
HessDR, AcostaFL, RitzRH, KacmarekRM, CamargoCA. The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Chest., 1999; 115(1):184–189. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9925082
139.
RodrigoGJ, Castro-RodriguezJA. Heliox-driven β2-agonists nebulization for children and adults with acute asthma: a systematic review with meta-analysis. Ann Allergy, Asthma Immunol., 2014; 112(1):29–34. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24331390
140.
BrandaoDC, BrittoMC, PessoaMF, de SaRB, AlcoforadoL, MatosLO, et al.Heliox and forwardleaning posture improve the efficacy of nebulized bronchodilator in acute asthma: a randomized trial. Respir Care. 2011; 56(7):947–952. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21352660
141.
deBoisblancBP, DeBleiuxP, ResweberS, FuscoEE, SummerWR. Randomized trial of the use of heliox as a driving gas for updraft nebulization of bronchodilators in the emergent treatment of acute exacerbations of chronic obstructive pulmonary disease. Crit Care Med., 2000; 28(9):3177–3180. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11008978
142.
HurfordWE, CheifetzIM. Respiratory controversies in the critical care setting. Should heliox be used for mechanically ventilated patients? Respir Care. 2007; 52(5):582–591; discussion 591-4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17484790
